First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation

作者
Baohui Han,Solange Peters,Anh Tuấn Lê,Dingzhi Huang,G. Wu,Lejie Cao,Cẩm Phương Phạm,Jun Zhao,Kai Wang,Nong Yang,Hua Zhong,Youyou Hu,Stefanie Morris,Verena Lam,Vilma Graupner,Barbara Jennifer Gitlitz,Elen Höglander,C Schulz,Siow Ming Lee
出处
期刊:Chinese Medical Journal [Lippincott Williams & Wilkins]
卷期号:139 (12): 1838-1845 被引量:1
标识
DOI:10.1097/cm9.0000000000003796
摘要

BACKGROUND: Lung cancer remains a significant medical problem in Asia, and improved treatments are needed for patients diagnosed with non-small cell lung cancer (NSCLC), who are frail with poor performance status or substantial comorbidities. This study aimed to investigate the efficacy and safety of first-line atezolizumab vs . single-agent chemotherapy in the Asian subpopulation in IPSOS trial. METHODS: This exploratory analysis of the Asian subpopulation from the phase 3, global, open-label, randomized controlled IPSOS trial evaluated the efficacy and safety of atezolizumab (1200 mg intravenously every 3 weeks) vs . single-agent chemotherapy (investigator's choice of vinorelbine or gemcitabine) as first-line treatment in patients with locally advanced or metastatic NSCLC, who were ineligible for platinum-based chemotherapy. The primary outcome was overall survival (OS); other outcomes were progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety. RESULTS: Seventy patients from China and Vietnam were included. Median OS was 15.8 months in the atezolizumab group vs . 12.5 months in the chemotherapy group; unstratified hazard ratio, 0.74 (95% confidence interval 0.41, 1.35). Median PFS was 8.1 months vs . 5.4 months, ORR was 27.9% vs . 7.4%, and median DOR was 18.7 months vs . 9.3 months, in the atezolizumab group vs . in the chemotherapy group, respectively. All-grade and grade 3-4 treatment-related adverse events (AEs) were less frequent with atezolizumab compared with chemotherapy. Two patients in the atezolizumab group had grade 5 AEs, namely pneumonia and acute left ventricular failure, with the latter considered treatment-related. CONCLUSIONS: Atezolizumab showed encouraging efficacy results and was well tolerated in an Asian subpopulation of patients with NSCLC who were deemed ineligible for standard platinum-based chemotherapy. The findings of this exploratory subpopulation analysis were consistent with those for the global IPSOS population. REGISTRATION: ClinicalTrials.gov , NCT03191786.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
coff完成签到,获得积分10
刚刚
1秒前
研友_ZG4ml8发布了新的文献求助10
1秒前
学术的刘完成签到,获得积分10
1秒前
Allen完成签到,获得积分10
2秒前
牧芷珊完成签到,获得积分10
2秒前
阿柠完成签到,获得积分10
2秒前
研友_Zbb4mZ完成签到,获得积分10
2秒前
三七二一完成签到,获得积分10
2秒前
3秒前
JamesPei的应助被爱在西元前采纳,获得10
3秒前
奋斗蝴蝶发布了新的文献求助10
4秒前
陈zw完成签到,获得积分10
4秒前
4秒前
zzzzlllll完成签到,获得积分10
4秒前
Sue完成签到,获得积分10
5秒前
rrr完成签到,获得积分10
5秒前
ZYX完成签到,获得积分10
5秒前
喜悦白玉发布了新的文献求助10
6秒前
ZJ完成签到,获得积分10
6秒前
6秒前
wanci的应助被瘦瘦滢采纳,获得10
6秒前
拉普拉斯开始变换完成签到,获得积分10
6秒前
molihuakai的应助被方苠采纳,获得10
6秒前
feiyue126发布了新的文献求助10
6秒前
7秒前
skmksd发布了新的文献求助10
7秒前
登山者完成签到,获得积分10
7秒前
幸运鱼完成签到,获得积分10
7秒前
小明同学呀完成签到,获得积分10
8秒前
yi完成签到,获得积分10
8秒前
8秒前
joyli完成签到,获得积分10
8秒前
阿白完成签到,获得积分10
9秒前
9秒前
李健的小迷弟的应助被Lily采纳,获得10
9秒前
嘻嘻哈公主完成签到 ,获得积分20
9秒前
哈尼完成签到,获得积分10
9秒前
酷酷冷亦完成签到,获得积分10
9秒前
苹果骑士完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039